Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21447367 | 0.82 | OPRD1 (0.64) | OPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL21447366 | 0.82 | OPRD1 (0.64) | OPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL30980868 | 0.82 | OPRD1 (0.64) | OPRD1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL21447427 | 0.82 | OPRD1 (0.60) | OPRD1OPRM1OPRK1ALDH1A1LMNA | |
| SCHEMBL23357025 | 0.81 | SMN1; SMN2 (0.49) | OPRD1OPRM1SMN1; SMN2HTTOPRK1 | |
| SCHEMBL21447463 | 0.81 | SMN1; SMN2 (0.49) | OPRD1OPRM1SMN1; SMN2HTTOPRK1 | |
| SCHEMBL30980901 | 0.81 | SMN1; SMN2 (0.49) | OPRD1OPRM1SMN1; SMN2HTTOPRK1 | |
| SCHEMBL23375498 | 0.80 | OPRD1 (0.63) | OPRD1OPRM1OPRK1ALDH1A1LMNA | |
| SCHEMBL23375715 | 0.80 | OPRD1 (0.63) | OPRD1OPRM1OPRK1ALDH1A1LMNA | |
| SCHEMBL21447664 | 0.80 | SMN1; SMN2 (0.48) | OPRD1OPRM1SMN1; SMN2HTTOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | EPIODYNE, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2019195634-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885SMN1; SMN2 3077/4885 |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885SMN1; SMN2 3077/4885 |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885SMN1; SMN2 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.